S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
J&J, Gilead, BMS: A look at undervalued dividend payers
The 4 highest-shorted large-cap stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The JD.com train is getting ready to leave the station again
3 stocking stuffers you can buy for yourself
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
J&J, Gilead, BMS: A look at undervalued dividend payers
The 4 highest-shorted large-cap stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The JD.com train is getting ready to leave the station again
3 stocking stuffers you can buy for yourself
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
J&J, Gilead, BMS: A look at undervalued dividend payers
The 4 highest-shorted large-cap stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The JD.com train is getting ready to leave the station again
3 stocking stuffers you can buy for yourself
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
J&J, Gilead, BMS: A look at undervalued dividend payers
The 4 highest-shorted large-cap stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The JD.com train is getting ready to leave the station again
3 stocking stuffers you can buy for yourself

Rubius Therapeutics Stock Price, News & Analysis (NASDAQ:RUBY)

$0.02
0.00 (0.00%)
(As of 11/29/2023 ET)
Compare
Today's Range
$0.0181
$0.0190
50-Day Range
$0.02
$0.02
52-Week Range
$0.00
$0.42
Volume
20,119 shs
Average Volume
1.24 million shs
Market Capitalization
$1.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

RUBY stock logo

About Rubius Therapeutics Stock (NASDAQ:RUBY)

Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.

RUBY Stock Price History

RUBY Stock News Headlines

Rubius Therapeutics Inc RUBY
RUBY - Rubius Therapeutics, Inc.
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
North American Morning Briefing: Alphabet, -2-
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Former Rubius CEO jumps to another Flagship spinout
Rubius Therapeutics, Inc. (RUBY)
Rubius Therapeutics Inc
Flagship-backed Vesalius lays off 43%
Rubius Therapeutics scraps platform, lays off 160
Rubius Therapeutics Announces Strategic Update
Rubius Therapeutics to Provide Strategic Update
See More Headlines
Receive RUBY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rubius Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
11/29/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RUBY
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.17 per share

Miscellaneous

Free Float
85,687,000
Market Cap
$1.72 million
Optionable
Not Optionable
Beta
2.23
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Laurence A. Turka M.D. (Age 65)
    Chief Scientific Officer and Head of Research & Translational Medicine
    Comp: $626.55k
  • Mr. Craig R. Jalbert CIRA (Age 61)
    President, Treasurer, CS, Principal Exe Officer, Interim Principal Fin. & Acc. Off. and Director
  • Ms. Marissa Hanify
    Director of Corporate Communications














RUBY Stock Analysis - Frequently Asked Questions

How have RUBY shares performed in 2023?

Rubius Therapeutics' stock was trading at $0.1750 at the beginning of the year. Since then, RUBY shares have decreased by 89.1% and is now trading at $0.0190.
View the best growth stocks for 2023 here
.

How were Rubius Therapeutics' earnings last quarter?

Rubius Therapeutics, Inc. (NASDAQ:RUBY) announced its quarterly earnings results on Monday, November, 8th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.01. During the same period in the previous year, the firm earned ($0.51) earnings per share.

What is Pablo Cagnoni's approval rating as Rubius Therapeutics' CEO?

12 employees have rated Rubius Therapeutics Chief Executive Officer Pablo Cagnoni on Glassdoor.com. Pablo Cagnoni has an approval rating of 91% among the company's employees. This puts Pablo Cagnoni in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Rubius Therapeutics own?
When did Rubius Therapeutics IPO?

(RUBY) raised $200 million in an IPO on Wednesday, July 18th 2018. The company issued 9,500,000 shares at a price of $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners served as the underwriters for the IPO.

Who are Rubius Therapeutics' major shareholders?

Rubius Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Dannielle Appelhans, David R Epstein, Laurence A Turka, Maiken Keson-Brookes, Pablo J Cagnoni and Ventures Fund Iv Gene Flagship.
View institutional ownership trends
.

How do I buy shares of Rubius Therapeutics?

Shares of RUBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:RUBY) was last updated on 11/30/2023 by MarketBeat.com Staff

My Account -